Conference Reports for NATAP

Back

HIV R4P Jan & 27 - 28 Feb 3 & 4 - 2021     The AMP Studies: Phase 2b Proof-of-Concept Trials Designed to Test the Efficacy of VRC01 Antibody to Prevent HIV Acquisition - (02/05/21)   Social, economic, mental health, and medical care impacts of COVID-19 in a US cohort of sexual and gender minority adolescents and young adults (SGM AYA) at-risk for HIV - (02/05/21)   US COVID-19 Prevention Network Outlines Goals, Shows Moderna Trial Impact - Mark Mascolini - (02/04/21)   With COVID Here, Mental Health, Money Woes Grow in US Sex- and Gender-Minority Youth - Mark Mascolini - (02/04/21)   Low and Transient Rectal Dapivirine Levels in 7-Day Rectal Gel Trial - Mark Mascolini - (02/04/21)   Higher Rectal Penetration Needed With PC-1005 Microbicide Gel - Mark Mascolini - (02/04/21)   Climbing Rectal Gonorrhea Rate But Falling HIV Rate in British MSM - Mark Mascolini - (02/04/21)   Bottoms are up at the HIV Research for Prevention Virtual Conference - (02/04/21)   Only Half in Representative US Sample Intends to Get COVID Vaccine - Mark Mascolini - (02/03/21)   More Than One Quarter of People Feel No COVID Symptoms Before Shedding Virus - Mark Mascolini - (02/03/21)   Most US MSM Unaware of-and Not Interested in-As-Needed PrEP - Mark Mascolini - (01/29/21)   COVID Restraints Followed by More Condom-Free Sex, Less PrEP, in Amsterdam MSM - Mark Mascolini (01/29/21)   Steep Dapivirine Drops in Vaginal Fluid With Cyclic Use of DPV/LNG Vaginal Ring - Mark Mascolini- (01/29/21)   PK Goals Met With 90-Day TFV/LNG Vaginal Ring in 47-Woman Randomized Trial - Mark Mascolini - (01/29/21)   Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021 - (01/29/21)   Early Data Hint Once-Monthly Oral PrEP Feasible With Novel Antiretroviral - Mark Mascolini - (01/29/21)   VARIABLE HIV SEROINCIDENCE RATES IN A COHORT OF HIGH-RISK MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN IN CHINA - (01/29/21)   Impact of UGT Induction by Rifampin and Rifabutin on Cabotegravir Long-Acting Pharmacokinetics for HIV Pre-exposure Prophylaxis (PrEP) using Population Pharmacokinetic Modeling and Simulation - (01/29/21)   MRI EXAMINATION OF CABOTEGRAVIR LONG-ACTING FORMULATION DEPOT KINETICS IN HEALTHY ADULT VOLUNTEERS - (01/29/21)   DISTRIBUTION OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) IN PLASMA, MUCOSAL TISSUES, AND ASSOCIATED FLUIDS AFTER A SINGLE ULTRASOUND-GUIDED INTRAMUSCULAR (IM) INJECTION IN HEALTHY ADULT PARTICIPANTS - (01/29/21)   Utilization Patterns and HIV Incidence Within the First Year of Initiation of TDF/FTC for HIV Pre-exposure Prophylaxis (PrEP) Among Insured Individuals in the US - (01/28/21)   Biodegradable TAF Implants Protect 6 of 6 Macaques From Vaginal SHIV - Mark Mascolini - (01/28/21)   Trial design, enrollment status, demographics, and pharmacokinetic (PK) data from a blinded interim analysis from a phase 2a trial of islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP) - (01/28/21)   Over One Third of New HIV Diagnoses in North Carolina Involve Recent Infection - Mark Mascolini - (01/28/21)   Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084 - (01/28/21)   Design and testing of a cabotegravir reservoir implant for HIV prevention - (01/28/21)   User Wish List for Microarray Patch to Prevent HIV and Pregnancy: Small, Discreet, Easy to Use, Long-Acting - Mark Mascolini - (01/28/21)   High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamide - (01/27/21)   Understanding HIV prevention from the perspective of adolescent girls and young women at high risk of HIV infection - (01/26/21)   Sex work in the wake of SARSCoV2 in Zimbabwe: A qualitative study - (01/26/21)   Shelter-in-place but at what cost? Barriers to healthcare and other social determinants of health among young women under South Africa's COVID-19 lockdown - (01/26/21)   High resolution and 3D ultrasound imaging of implant and intravaginal ring drug delivery devices during HIV pre-exposure prophylaxis (PrEP) preclinical and clinical studies - (01/26/21)   Switching from F/TDF to F/TAF for HIV Pre-exposure Prophylaxis: An Analysis of the Real-World Data - (01/26/21)   Long-Acting CAB Superior to Daily Oral TDF/FTC in Preventing HIV in Women - Mark Mascolini - (01/26/21)   Antibody Infusions Prevent Acquisition of Some HIV Strains, NIH Studies Find - (01/26/21)